Search Results
Your search for can matches 13753 pages
Showing 2351 - 2400Study Investigates Potential Embryonic Origin of Medulloblastomas
Medulloblastomas may exist in a premalignant form at birth after initially developing during the first or second trimester of pregnancy, according to a new international study published by Hendrikse et al in Nature. As medulloblastomas typically present around age 7, the team’s discovery is the...
Research Examines a New Tool for Discovering Cancer-Driving Structural Variations
An advanced software tool for analyzing DNA sequences from tumor samples has uncovered new, likely cancer-driving genes. In a study, Weill Cornell Medicine researchers designed the software, known as CSVDriver, to map and analyze the locations of large mutations, known as structural variants, in...
Oncologist Use of Reduced Doses of New Systemic Treatments in Patients With Metastatic Cancer
In a survey study reported in JCO Oncology Practice, Jimenez et al found that half of surveyed oncologists reported sometimes or usually using reduced doses at initiation of a new systemic treatment in patients with metastatic cancer in order to potentially reduce toxicity. Study Details The study...
Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
In a single-institution study reported in JAMA Oncology, Allen S. Ho, MD, and colleagues found evidence that active surveillance may be a suitable treatment for most patients with low-risk papillary thyroid carcinoma. Study Details The prospective study included 222 patients enrolled at...
Real-World Experience With Durvalumab at the Mayo Clinic Mirrors PACIFIC Trial Findings
Concurrent chemoradiation therapy followed by durvalumab has become the standard of care in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC), based on the PACIFIC trial.1 However, clinical trials have predetermined inclusion and exclusion criteria, and they evaluate...
Expert Point of View: Jacek Jassem, MD
Abstract discussant Jacek Jassem, MD, of the Medical University of Gdansk, Poland, underscored smoking as the most important cause of lung cancer, noting that between 85% and 90% of patients with lung cancer are current or former smokers. “Lung cancer screening, which has recently become standard...
Study Finds High-Intensity Intervention Helped One-Third of Participants in Lung Cancer Screening Program to Quit Smoking
Despite significant advancements in cancer therapy, the number-one stopper of lung cancer remains the most basic intervention: quitting smoking. Unfortunately, for long-term smokers, that intervention can sometimes be the most challenging. According to data presented during the International...
Expert Point of View: Anand Devaraj, MD, PhD
Abstract discussant Anand Devaraj, MD, PhD, Professor in Thoracic Radiology at Royal Brompton and Harefield Hospitals, and Professor of Thoracic Radiology at the National Heart and Lung Institute, Imperial College London, highlighted the increased risk of second primary tumors among current...
Expert Point of View: Anand Devaraj, MD, PhD
Abstract discussant Anand Devaraj, MD, PhD, a thoracic radiologist at Royal Brompton and Harefield hospitals, and Professor of Thoracic Radiology at the National Heart and Lung Institute, Imperial College London, noted that both the Nederlands-Leuvens Longkanker Screenings Onderzoek (NELSON) trial...
Expert Point of View: Corinne Faivre-Finn, MD, PhD, and Masahiro Tsuboi, MD
The first discussant of the NADIM II study, Corinne Faivre-Finn, MD, PhD, Professor of Thoracic Radiation Oncology, University of Manchester, and Honorary Consultant Clinical Oncologist at The Christie NHS Foundation Trust, Manchester, England, called the results “very impressive” but noted that...
DeFi Trial: Novel Gamma Secretase Inhibitor Halts Progression of Desmoid Tumors
Patients with rare desmoid tumors may finally have an effective treatment. A first-in-class gamma secretase inhibitor, nirogacestat, led to an improvement in progression-free survival in the phase III DeFi trial. The results were presented during the Presidential Symposium at the European Society...
Tissue vs ctDNA NGS for Detecting Actionable Alterations in Patients With Advanced Cancer
A large prospective analysis, published by Bayle et al in Annals of Oncology, evaluated differences between tissue and circulating tumor DNA (ctDNA) next-generation sequencing (NGS) with a large cancer gene panel. The investigators compared the impacts of both methods in terms of molecular tumor...
Inflammatory Markers and Clinical Decline After Adjuvant Chemotherapy in Older Women With Breast Cancer
As reported in the Journal of Clinical Oncology by Ji et al, the HOPE study (Hurria Older Patients [HOPE] with Breast Cancer Study) has shown that older women categorized as robust prior to adjuvant chemotherapy are at risk for clinical decline postchemotherapy, with high baseline levels of the...
Outcomes After Nonresponse and Relapse in Children and Young Adults Receiving Tisagenlecleucel for B-Cell ALL
In a retrospective study reported in the Journal of Clinical Oncology, Schultz et al found poor survival among children and young adults with lack of response to tisagenlecleucel for B-cell acute lymphoblastic leukemia (ALL). Salvage therapy after relapse was capable of inducing responses, but...
Study Examines Potential Benefits of a Fourth COVID-19 Vaccination for Patients With Cancer
A research team led by Matthias Preusser, MD, PhD, Professor of Medical Oncology and Head of the Clinical Division of Oncology at the Medical University of Vienna, had already demonstrated that patients with cancer may benefit from a third vaccination to protect them against COVID-19. A recent...
Lasker Foundation Announces 2022 Lasker Award Winners
On September 28, the Lasker Foundation announced the winners of the 2022 Albert Lasker Basic Medical Research Award, the 2022 Lasker~DeBakey Clinical Medical Research Award, and the 2022 Lasker~Bloomberg Public Service Award. Albert Lasker Basic Medical Research Award Richard O. Hynes, PhD, of the...
Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Nivolumab Monotherapy or in Combination Therapy
Marleen Kok, MD, PhD, of The Netherlands Cancer Institute in Amsterdam, discusses the initial results from the BELLINI trial, which tested whether short-term preoperative nivolumab, either as monotherapy or in combination with low-dose doxorubicin or novel immunotherapy combinations, can induce...
Unhealthy Gut May Set the Stage for Breast Cancer to Spread, Preclinical Research Reveals
An unhealthy gut triggers changes in normal breast tissue that may help breast cancer metastasize, according to new, early research from the University of Virginia (UVA) Cancer Center published by Feng et al in Cancer Immunology Research. The researchers found that when the gut microbiome is...
Genomic Testing May Aid in Identifying Patients of African Descent With High-Risk Prostate Cancer
Black patients of African descent tend to be diagnosed more frequently with prostate cancer and have higher mortality rates than patients of other races and ethnicities. Despite this substantial disparity, few prospective studies focused on maximizing the recruitment of African American patients...
Research Finds Medicaid Expansion Led to Decreases in Cancer Incidence and Mortality Rates
State-run Medicaid insurance, expanded in 2014 as part of the Affordable Care Act, has resulted in decreased metastatic cancer incidence rates as well as decreased overall cancer mortality rates, and has averted over 1,000 deaths due to cancer per year. About 12% of the improvements in cancer...
Can a Navigation Program Lower Care Costs for Patients With Cancer?
A cancer navigation program can reduce overall costs when deployed in collaboration with a statewide Medicare Advantage health plan across a wide range of practice types, according to findings to be presented by Worland et al at the upcoming 2022 ASCO Quality Care Symposium (Abstract 4). A...
Total Cost of Cancer Care May Be Reduced With Lower-Cost Alternate Drugs Without Compromising Quality of Care
Substituting biosimilars, generics, and clinically appropriate lower-cost drugs for established, costlier drugs was shown to be an effective way to reduce the total cost of care, by 5% or so, while maintaining the quality of care for patients with cancer. Even small shifts toward lower-cost drugs...
A Physicist Father Inspired a Love of Science in Oncology Researcher Stanton L. Gerson, MD
In this installment of the Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Stanton (“Stan”) L. Gerson, MD, Dean and Senior Vice President for Medical Affairs, School of Medicine, and Acting Director of the Case Comprehensive Cancer Center and National Center for...
Exercise Therapy Across the Cancer Care Continuum
Guest Editor’s Note: Several studies have shown that regular physical activity helps to reduce the symptom burden and improve disease-related outcomes in patients with cancer. In this article, Jessica M. Scott, PhD, and Neil M. Iyengar, MD, summarize the current evidence surrounding exercise...
Changing the Algorithm for Relapsed or Refractory Large B-Cell Lymphomas
Despite a significant potential for cure, relapsed and refractory large B-cell lymphomas (LBCL) comprise the most common cause of lymphoma-related mortality. Sequential relapses reflect the limits of repeated exposure to chemotherapy, even when delivered at high doses. More than 30 years ago,...
Diversify Cancer Clinical Trials With New Recruitment and Retention Resources
ASCO and the Association of Community Cancer Centers (ACCC) jointly released two resources to help research sites increase racial and ethnic equity, diversity, and inclusion (EDI) in cancer clinical trials. The Just ASK™ Increasing Diversity in Cancer Clinical Research: An ACCC-ASCO Training...
Determining Prognosis in Aggressive Lymphomas: Integrating Liquid Biopsy Into Imaging Assessment
The incorporation of blood-based measurements—ie, “liquid biopsies”—into imaging assessment may refine the accuracy of prognosis in aggressive lymphomas, as described by David Kurtz, MD, PhD, Assistant Professor in the Division of Oncology, Stanford University Medical Center, in a talk at the 2022...
Geriatric Oncology and Hematology in Singapore
Globally, the population is aging, with the number of people aged 60 and older projected to double from 1 billion worldwide in 2020 to 2.1 billion by 2050. Given the aging population, coupled with the risk of cancer increasing with age, an exponential rise in cases of older adults diagnosed with...
Patients With Multiple Myeloma May Face CAR T-Cell Shortages
From microchips to automobiles, people in the United States are experiencing shortages of all kinds of products, and oncology treatments are no exception. In particular, shortages related to chimeric antigen receptor (CAR) T-cell therapy have been reported, most acutely, for B-cell maturation...
Expert Point of View: Anand Devaraj, MD, PhD
Abstract discussant Anand Devaraj, MD, PhD, a thoracic radiologist at Royal Brompton and Harefield hospitals, and Professor of Thoracic Radiology at the National Heart and Lung Institute, Imperial College London, noted that both the Nederlands-Leuvens Longkanker Screenings Onderzoek (NELSON) trial...
What the Supreme Court’s Abortion Decision Means for Patients With Cancer and Their Clinicians
On June 24, 2022, the Supreme Court ruled in Dobbs v Jackson Women’s Health Organization (Dobbs)1 and overturned Roe v Wade and Planned Parenthood v Casey, which recognized a federal constitutional right to end a pregnancy up to the point of viability. This decision opened the door for states to...
Expert Point of View: Corinne Faivre-Finn, MD, PhD and Masahiro Tsuboi, MD
The first discussant of the NADIM II study, Corinne Faivre-Finn, MD, PhD, Professor of Thoracic Radiation Oncology, University of Manchester, and Honorary Consultant Clinical Oncologist at The Christie NHS Foundation Trust, Manchester, England, called the results “very impressive” but noted that...
AACR Cancer Progress Report 2022 Shows Cancer Mortality Rates Continue to Decline, but Challenges Remain
Advances in more effective treatment and early detection diagnostics, coupled with reductions in smoking rates, have resulted in a 32% decline in cancer mortality in the United States since 1991, translating into nearly 3.5 million lives saved, according to the newly released American Association...
September 24 Is World Cancer Research Day
September 24 is World Cancer Research Day, an initiative organized by a collaboration of professional societies, research organizations, and other institutions. In advance of the event, the following declaration was published in order to outline the goals of the initiative: Cancer is projected to...
Study Shows Many Patients Prefer Stool Test to Colonoscopy for Colorectal Cancer Screening
Three-quarters of surveyed people preferred to do a fecal immunochemical test (FIT) rather than undergo a colonoscopy for their regular colorectal cancer screening, according to a new Cedars-Sinai study published by Makaroff et al in Clinical Gastroenterology and Hepatology. “One of the big issues...
Precision Physical Activity Prescriptions May Improve Survival in Patients With Stage III Colon Cancer
Physical activity may be associated with improved outcomes for patients undergoing postoperative treatment for stage III colon cancer, according to findings from a new study out of Pennington Biomedical Research Center published by Brown et al in the Journal of Clinical Oncology. The study assessed ...
New Imaging Technique May Improve Accuracy of Basal Cell Carcinoma Diagnosis
A novel imaging technique may significantly improve the accuracy of the diagnosis of basal cell carcinoma (BCC) compared to clinical and dermoscopic examinations alone, according to new research presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress. The study found...
Housing Instability and Risk of Mortality in Patients With Cancer
Little is known about patients with cancer’s social welfare and how it affects their health outcomes. To address this, researchers at University of California (UC) San Diego School of Medicine and partnering institutions assessed the prevalence and impact of various social risk factors in patients...
Study Finds Cancer Mortality Rates Correlate With Geography as Well as Known Behavioral Risk Factors
Researchers at Case Western Reserve University have found that risk factors historically linked to cancer mortality vary regionally across the lower 48 United States—such that they believe those differences should be considered in developing tailored public-health interventions. Dong et al...
Neoadjuvant Endocrine Therapy May Elicit Differential Responses in Black vs White Women With Breast Cancer
Black women treated with neoadjuvant endocrine therapy for breast cancer were more likely to benefit than White women if treated at an earlier disease stage, but less likely to benefit than White women if treated at a later disease stage, according to results presented at the 15th American...
Many Families of Children With Leukemia May Experience Food Insecurity That Is Not Alleviated by Federal Assistance Program
Nearly one in four families of pediatric patients with acute lymphoblastic leukemia (ALL) enrolled in a clinical trial experienced food insecurity, and almost half of the families eligible for the Supplemental Nutrition Assistance Program (SNAP) did not receive benefits. In addition, receiving SNAP ...
'Real-World' Experience With Durvalumab at the Mayo Clinic Mirrors PACIFIC Findings
Concurrent chemoradiation followed by durvalumab has become the standard of care in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC), based on the PACIFIC trial.1 But clinical trials have predetermined inclusion and exclusion criteria, and they evaluate selective...
Novel Photon-Counting CT May Improve Myeloma Bone Disease Detection
New computed tomography (CT) technology paired with artificial intelligence (AI)-based noise reduction may offer superior detection of bone disease associated with multiple myeloma at lower radiation doses than conventional CT, according to a recent study published by Baffour et al in Radiology....
National Lung Screening Trial Results Highlight Importance of Lifelong Follow-up
Approximately 6% of patients with stage I to III lung cancer develop a second primary lung cancer within 5 years of their initial diagnosis, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer.1 Analysis of data...
Costs of Cancer Treatment for Younger, Privately Insured Patients
A new, large study led by researchers at the American Cancer Society (ACS) and The University of Texas MD Anderson Cancer Center showed the rising costs of cancer treatment led to increases in total costs of care, and when compounded with greater cost-sharing, increased out-of-pocket costs for...
Cost-Effectiveness of Chemotherapy Sequences in Metastatic Breast Cancer According to Prior Therapy Exposure
In a modeling study reported in the Journal of Clinical Oncology, Stephanie B. Wheeler, PhD, MPH, and colleagues identified the most cost-effective sequences of single-agent chemotherapy regimens among patients with endocrine-refractory or triple-negative metastatic breast cancer according to prior ...
Expert Point of View: Jacek Jassem, MD
Abstract discussant, Jacek Jassem, MD, of the Medical University of Gdansk, in Poland, underscored smoking as the most important cause of lung cancer, noting that between 85% and 90% of patients with lung cancer are current or former smokers. “Lung cancer screening, which has recently become...
High-Intensity Intervention Helps One-Third of Participants in Lung Cancer Screening Program Quit Smoking
Despite significant advancements in cancer therapy, a primary means to avoid lung cancer is prevention, and smoking cessation is the most basic intervention. Unfortunately, for long-term smokers, that intervention can sometimes be the most challenging. According to data presented during the...
Early Research Identifies Effective Combination Immunotherapy for Subgroup of Patients With Metastatic Colorectal Cancer
A physician-scientist at City of Hope has identified a novel combination immunotherapy regimen—a triplet therapy consisting of regorafenib, ipilimumab, and nivolumab—that demonstrated significant response in patients with chemotherapy-resistant, microsatellite-stable metastatic colorectal cancer....
Neoadjuvant Cemiplimab in Patients With Stage II to IV Cutaneous Squamous Cell Carcinoma
In an international, multicenter phase II clinical trial, 63.3% of patients with stage II to IV cutaneous squamous cell carcinoma saw their tumors nearly or completely eradicated when treated with the anti–PD-1 agent cemiplimab-rwlc before surgery. The results were presented by Gross et al at the...
